1 |
Benazzi F. Depressive mixed state: testing different definitions. Psychiatry Clin Neurosci 2001;55:647-652.
DOI
|
2 |
Benazzi F. Mixed states in bipolar II disorder: should full hypomania always be required? Psychiatry Res 2004;127:247-257.
DOI
|
3 |
Benazzi F, Akiskal HS. Delineating bipolar II mixed states in the Ravenna-San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes. J Affect Disord 2001;67:115-122.
DOI
|
4 |
Shim IH, Woo YS, Jun TY, Bahk WM. Mixed-state bipolar I and II depression: time to remission and clinical characteristics. J Affect Disord 2014;152-154:340-346.
DOI
|
5 |
Muneer A. Staging models in bipolar disorder: a systematic review of the literature. Clin Psychopharmacol Neurosci 2016;14:117-130.
DOI
|
6 |
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Wasington, DC:American Psychiatric Association;2000.
|
7 |
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
DOI
|
8 |
Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2016;173:400-407.
DOI
|
9 |
Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. CNS Spectr 2017;22:236-245.
DOI
|
10 |
Wang HR, Bahk WM, Seo JS, Woo YS, Park YM, Jeong JH, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci 2017;15:199-209.
DOI
|
11 |
McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 2017;78:703-713.
DOI
|
12 |
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70:1540-1547.
DOI
|
13 |
Patkar AA, Pae CU, Vohringer PA, Mauer S, Narasimhan M, Dalley S, et al. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol 2015;35:319-323.
DOI
|
14 |
Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectr 2017;22:228-235.
DOI
|
15 |
Sramek J, Loebel A, Murphy M, Mao Y, Pikalov A, Cutler NR. Lurasidone in post-menopausal females with major depressive disorder with mixed features: post-hoc analysis of a placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2017;78:12-17.
DOI
|
16 |
Goldberg J, Mao Y, Siu C, Tsai J, Pikalov A, Calabrese J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? Neuropsychopharmacology 2016;41:S515-S516.
|
17 |
Suppes T, Ostacher M. Mixed features in major depressive disorder: diagnoses and treatments. CNS Spectr 2017;22:155-160.
DOI
|
18 |
Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry 2009;70:1424-1431.
DOI
|
19 |
McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015;76:398-405.
DOI
|
20 |
Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord 2014;164:57-62.
DOI
|
21 |
Muralidharan K, Ali M, Silveira LE, Bond DJ, Fountoulakis KN, Lam RW, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. J Affect Disord 2013;150:408-414.
DOI
|
22 |
Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord 2003;73:113-122.
DOI
|
23 |
Akiskal HS, Benazzi F. Validating Kraepelin's two types of depressive mixed states: “depression with flight of ideas“and” excited depression”. World J Biol Psychiatry 2004;5:107-113.
DOI
|
24 |
Benazzi F. Depressive mixed states: unipolar and bipolar II. Eur Arch Psychiatry Clin Neurosci 2000;250:249-253.
DOI
|
25 |
Patkar A, Gilmer W, Pae CU, Vohringer PA, Ziffra M, Pirok E, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012;7:e34757.
DOI
|
26 |
Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry 2012;45:152-155.
DOI
|
27 |
Nelson C, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features: effect of baseline depression severity on clinical outcome. Eur Neuropsychopharmacol 2016;26(Suppl):S400-S401.
DOI
|
28 |
Pikalov A, Goldberg J, Mao Y, Siu C, Tsai J, Calabrese J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? Eur Psychiatry 2017;41 Suppl:S243.
|
29 |
Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 2017;22:203-219.
DOI
|
30 |
Pae CU, Vohringer PA, Holtzman NS, Thommi SB, Patkar A, Gilmer W, et al. Mixed depression: a study of its phenomenology and relation to treatment response. J Affect Disord 2012;136:1059-1061.
DOI
|
31 |
Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, et al. Korean Medication Algorithm for Depressive Disorders 2017: third revision. Clin Psychopharmacol Neurosci 2018;16:67-87.
DOI
|